Dumont & Blake Investment Advisors LLC Sells 4,360 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Dumont & Blake Investment Advisors LLC reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 50.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,360 shares of the medical research company's stock after selling 4,360 shares during the period. Dumont & Blake Investment Advisors LLC's holdings in Charles River Laboratories International were worth $859,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of CRL. Sunbelt Securities Inc. lifted its position in Charles River Laboratories International by 1,072.7% during the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company's stock valued at $70,000 after acquiring an additional 236 shares during the period. Thrive Wealth Management LLC raised its holdings in Charles River Laboratories International by 11.4% in the first quarter. Thrive Wealth Management LLC now owns 1,076 shares of the medical research company's stock worth $292,000 after buying an additional 110 shares during the last quarter. Congress Wealth Management LLC DE raised its holdings in Charles River Laboratories International by 0.9% in the first quarter. Congress Wealth Management LLC DE now owns 54,316 shares of the medical research company's stock worth $14,717,000 after buying an additional 500 shares during the last quarter. Woodmont Investment Counsel LLC purchased a new position in Charles River Laboratories International in the first quarter worth about $218,000. Finally, Norden Group LLC raised its holdings in Charles River Laboratories International by 2,642.3% in the first quarter. Norden Group LLC now owns 31,399 shares of the medical research company's stock worth $8,508,000 after buying an additional 30,254 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on CRL shares. StockNews.com raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, October 16th. UBS Group decreased their target price on shares of Charles River Laboratories International from $290.00 to $240.00 and set a "buy" rating for the company in a report on Thursday, August 8th. JPMorgan Chase & Co. cut shares of Charles River Laboratories International from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. TD Cowen decreased their target price on shares of Charles River Laboratories International from $228.00 to $203.00 and set a "hold" rating for the company in a report on Monday, August 12th. Finally, Evercore ISI lowered shares of Charles River Laboratories International from an "outperform" rating to an "inline" rating and reduced their price target for the stock from $225.00 to $190.00 in a research note on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus target price of $209.00.

Charles River Laboratories International Stock Performance

NYSE CRL traded down $0.61 during trading hours on Friday, hitting $182.12. 500,314 shares of the company's stock traded hands, compared to its average volume of 601,626. The business's fifty day moving average price is $196.23 and its two-hundred day moving average price is $212.16. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $9.38 billion, a P/E ratio of 21.43, a P/E/G ratio of 5.11 and a beta of 1.36. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.41. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. Equities research analysts predict that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International declared that its board has authorized a share buyback program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).